Lipid mediators of inflammation in obesity-Related glomerulopathy

Nephrology Dialysis Transplantation

Volumn 28, Issue SUPPL.4, 2013, Pages

  Nolan, Eileen ^a,b   O'Meara, Yvonne M ^a,b   Godson, Catherine ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Adipokines; Inflammation; Mononuclear cells; Obesity; Pro Resolving lipid mediators

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHEMERIN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; GLUCOSE TRANSPORTER 4; INSULIN RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; LEPTIN; LEPTIN RECEPTOR; LIPOXIN A; MELANOCORTIN 4 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYUNSATURATED FATTY ACID; RESISTIN; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ADRENERGIC SYSTEM; CHRONIC KIDNEY DISEASE; COLLAGEN SYNTHESIS; CYTOKINE RELEASE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; FATTY ACID SYNTHESIS; GLOMERULOPATHY; HORMONE SYNTHESIS; HUMAN; IMMUNOREGULATION; INFLAMMATION; INSULIN SENSITIVITY; KIDNEY FIBROSIS; KIDNEY FUNCTION; MACROPHAGE; MEDIATOR RELEASE; NONHUMAN; OBESITY; OBESITY RELATED GLOMERULOPATHY; PODOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; RENAL PROTECTION; RENOVASCULAR HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; SYMPATHETIC INNERVATION;

ADIPOKINES; INFLAMMATION; MONONUCLEAR CELLS; OBESITY; PRO-RESOLVING LIPID MEDIATORS;

ANIMALS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INFLAMMATION MEDIATORS; LIPID METABOLISM; OBESITY;

EID: 84890100734     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft392     Document Type: Review

References (50)

1. Weisinger JR, Kempson RL, Eldridge FL et al. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med 1974; 81: 440-447
2. Kramer H, Luke A, Bidani A et al. Obesity and prevalent and incident CKD: the hypertension detection and follow-Up program. Am J Kidney Dis 2005; 46: 587-594
3. Othman M, Kawar B, El Nahas AM. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study. Nephron Clin Pract 2009; 113: c16-c23
4. Tsuboi N, Koike K, Hirano K et al. Clinical features and longterm renal outcomes of japanese patients with obesity-related glomerulopathy. Clin Exp Nephrol 2013; 17: 379-385
5. Satirapoj B, Supasyndh O, Mayteedol N et al. Obesity and its relation to chronic kidney disease: a population-based, crosssectional study of a Thai army population and relatives. Nephrology (Carlton) 2013; 18: 229-234
6. Yoon YS, Park HS, Yun KE et al. Obesity and metabolic syndrome- related chronic kidney disease in nondiabetic, nonhypertensive adults. Metabolism 2009; 58: 1737-1742
7. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509
8. Tang J, Yan H, Zhuang S. Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol 2012; 608397
9. Gunta SS, Mak RH. Is obesity a risk factor for chronic kidney disease in children? Pediatr Nephrol 2012; 28: 1949-1956
10. Serra A, Romero R, Lopez D et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int 2008; 73: 947-955
11. Mathew AV, Okada S, Sharma K. Obesity related kidney disease. Curr Diabetes Rev 2011; 7: 41-49
12. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435
13. Couzin-Frankel J. Inflammation bares a dark side. Science 2010; 330: 1621
14. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002; 2: 787-795
15. Gonzalez-Periz A, Claria J. Resolution of adipose tissue inflammation. ScientificWorldJournal 2010; 10: 832-856
16. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J 2011; 75: 2739-2748
17. Wolf G, Chen S, Han DC et al. Leptin and renal disease. Am J Kidney Dis 2002; 39: 1-11
18. Shankar A, Syamala S, Xiao J et al. Relationship between plasma leptin level and chronic kidney disease. Int J Nephrol 2012; 2012: 269532
19. Wolf G, Hamann A, Han DC et al. Leptin stimulates proliferation cand TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [see comments]. Kidney Int 1999; 56: 860-872
20. Nasrallah MP, Ziyadeh FN. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol 2013; 33: 54-65
21. Yano Y, Hoshide S, Ishikawa J et al. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J Clin Hypertens (Greenwich) 2007; 9: 775-782
22. Sharma K, Ramachandrarao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656
23. Rutkowski JM, Wang ZV, Park AS et al. Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol 2013; 24: 268-282
24. Kim JE, Lee MH, Nam DH et al. Celastrol, an NF-kappaB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice. PLoS One 2013; 8: e62068
25. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35
26. Lumeng CN, DelProposto JB, Westcott DJ et al. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008; 57: 3239-3246
27. Ziegler-Heitbrock L, Ancuta P, Crowe S et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-e80
28. Ancuta P, Liu KY, Misra V et al. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics 2009; 10: 403
29. Rogacev KS, Ulrich C, Blomer L et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J 2010; 31: 369-376
30. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009; 49: 123-150
31. Anderson BM, Ma DW. Are all n-3 polyunsaturated fatty acids created equal? Lipids Health Dis 2009; 8: 33
32. Fredman G, Serhan CN. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem J 2011; 437: 185-197
33. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 2011; 111: 5922-5943
34. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71(1 Suppl): 343S-348S
35. Maderna P, Godson C. Lipoxins: resolutionary road. Br J Pharmacol 2009; 158: 947-959
36. Serhan CN, Yang R, Martinod K et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206: 15-23
37. Murakami M. Lipid mediators in life science. Exp Anim 2011; 60: 7-20
38. Stables MJ, Gilroy DW. Old and new generation lipid mediators in acute inflammation and resolution. Prog Lipid Res 2011; 50: 35-51
39. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6: 1191-1197
40. Godson C, Mitchell S, Harvey K et al. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 2000; 164: 1663-1667
41. Claria J, Dalli J, Yacoubian S et al. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol 2012; 189: 2597-2605
42. White PJ, Arita M, Taguchi R et al. Transgenic restoration of longchain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes 2010; 59: 3066-3073
43. Neuhofer A, Zeyda M, Mascher D et al. Impaired local production of pro-resolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes 2013; 62: 1945-1956
44. Flachs P, Ruhl R, Hensler M et al. Synergistic induction of lipid catabolism and anti-inflammatory lipids in white fat of dietary obese mice in response to calorie restriction and n-3 fatty acids. Diabetologia 2011; 54: 2626-2638
45. Gonzalez-Periz A, Horrillo R, Ferre N et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. Faseb J 2009; 23: 1946-1957
46. Todoric J, Loffler M, Huber J et al. Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 2006; 49: 2109-2119
47. Hellmann J, Tang Y, Kosuri M et al. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. Faseb J 25: 2399-2407
48. Titos E, Rius B, Gonzalez-Periz A et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 2011; 187: 5408-5418
49. Borgeson E, McGillicuddy FC, Harford KA et al. Lipoxin A4 attenuates adipose inflammation. Faseb J 2012; 26: 4287-4294
50. Scher JU, Pillinger MH. 15d-PGJ2: The anti-inflammatory prostaglandin? Clin Immunol 2005; 114: 100-109